Drug intelligence / Profile preview

ammoxetine

Development stage: Phase 3
Lead developer: CSPC ZhongQi Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Ammoxetine is a novel small molecule, selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. for the treatment of Major Depressive Disorder. It is administered as enteric-coated tablets and is designed to offer more potent inhibition of serotonin and norepinephrine transporters, potentially leading to reduced adverse effects and hepatotoxicity compared to existing treatments.

Other names: Ammoxetine hydrochloride enteric-coated tablets

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on ammoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ammoxetine.

Explore the full profile